Thought Leadership & Other Media

We're pleased to announce that we will be attending ASGCT this year, running virtually from May 11 through the 14. Be sure to save some time to meet with our team, check out our two abstracts and presentations on lentiviral vector (LVV) and adeno-associated virus (AAV) – both of which we're thrilled to share with you and the community.  

AGC Biologics is a proud sponsor of Alliance for Regenerative Medicine's (ARM) Meeting on the Mediterranean virtual conference this April.  While we wish we could spend time with everyone in person, we know this event is going to be the next best thing. (Hopefully we can be together again next year!)

We're thrilled to announce the launch of our first ever television commercials – now running in the Greater Denver Area and focused on recruiting for our new  state-of-the-art facility in Boulder, Colorado. We have begun full-scale operations and are hiring across all departments. To learn more and apply, please visit our Boulders Careers page.

The on-demand webinar and Q&A “Large-Scale LVV Production: From Industry-Leading Process Development to High Quality GMP Vector,” with our own Giuliana Vallanti, Director of Development and Global R&D, Cell and Gene Therapy, and the panel of co-hosts is now available to watch for free.

Join AGC Biologics' own Mark Womack, Chief Business Officer and Ramin Baghirzade, Sr. Director and Global Cell and Gene Therapy (C&GT) Business Development, and a panel of co-hosts for an on-demand presentation of the C&GT Expert Roundtable on Streaming and Optimizing Viral Vector Bioprocess and Analytical Development, presented by BioInsights.

Byron Kneller, VP, Process Development, Seattle and Luca Alberici, General Manager, Milan, present AGC Biologics’ end-to-end CDMO protein expression and cell and gene therapy manufacturing capabilities at BIO-Europe in October, 2020. 

In this spotlight article, presented by BioInsights, Dr. Ramin Baghirzade, AGC Biologics' Global Head of Business Development for Cell & Gene Therapy, shares his expert insights on the state of the industry, and four inter-connected variables exerting pressure on therapeutics developers to improve their processes earlier in the product’s development.